Compound Reserpine Tablets

1Reserpine is an adrenergic neuron blocking antihypertensive drug. 2This product achieves antihypertensive, heart rate slowing and central nervous system inhibition by depleting adrenaline in peripheral sympathetic nerve endings, catecholamines and 5-hydroxytryptamine in the heart, brain and other tissues. The antihypertensive effect is mainly achieved by reducing cardiac output and peripheral resistance, and partially inhibiting cardiovascular reflexes. The effect of slowing the heart rate is not obvious in people with normal heart rate, but it is obvious in people with sinus tachycardia. 3Reserpine acts on the hypothalamus to produce a sedative effect, but it does not cause drowsiness and anesthesia. It does not change the electroencephalogram during sleep and can relieve anxiety, tension and headache in hypertensive patients. 4After experimental animals were given reserpine at doses lower than the clinical dose, they showed symptoms such as pupil constriction, eyelid relaxation and drooping, hypothermia, and accelerated gastrointestinal activity. Within the therapeutic dosage range of humans, there is only an increase in gastrointestinal activity. Mutagenicity test In vitro microbial reverse mutation test showed that reserpine 1-5000mcg had no mutagenic effect on four strains of S.typhimurium, and 0.3-10mg did not cause transformation of mouse fibroblasts. Reserpine caused some chromosomal aberrations in cultured mouse breast cancer cells, but the experimental results were still negative; reserpine had no chromosomal aberration effect on cultured human peripheral leukocytes, but mitotic figures increased. One study reported that a certain reserpine preparation caused chromosomal aberrations and dominant lethal mutations in mice within 10mg/kg; but another study showed that mice were intraperitoneally administered 0.92-4.6mg/kg, and no dominant lethal mutations occurred. Teratogenicity test Reserpine can pass through the placental barrier of guinea pigs and consume fetal catecholamine storage. Two small experiments showed that oral administration of 0.25 mg/kg of reserpine (equivalent to 35 times the maximum clinical dose) to rats did not affect fertility; reproductive studies showed that intramuscular or intraperitoneal administration of 1-2 mg/kg of reserpine (equivalent to 125-250 times the maximum clinical dose) in early pregnancy in rats had teratogenic effects, resulting in various fetal abnormalities such as anophthalmia, axial skeleton, and hydronephrosis. Giving 0.04 mg/kg of reserpine (10 times the maximum clinical dose) to rabbits in early or late pregnancy can terminate pregnancy. Carcinogenicity experiments on rodents showed that reserpine is an animal carcinogen. Feeding animals with reserpine at a concentration of 5-10 ppm (100-300 times the common clinical dose) in food for two years resulted in an increase in the incidence of breast fibroadenomas in female mice, malignant tumors of the seminal vesicles in male mice, and malignant tumors of the adrenal medulla in male rats. The mammary tumors may be related to the increase in prolactin levels caused by reserpine, because several other drugs with prolactin effects have been implicated in increased incidence of mammary tumors in rodents.

11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohen-16-carboxylic acid methyl ester The structural formula is: Molecular formula: C33H40N2O9 Molecular weight: 608.69

This product is a slightly yellow tablet or film-coated tablet or sugar-coated tablet, which appears slightly yellow after the coating is removed.

Early and mid-stage hypertension

Oral administration: 1-2 tablets at a time, 3 times a day.

Common symptoms include nasal congestion, increased gastric acid secretion, increased bowel movements, and other symptoms of parasympathetic nervous system dominance, as well as fatigue and weight gain.

1. Patients who are allergic to this product are prohibited from using it. 2. Patients with gastric and duodenal ulcers are prohibited from using it.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

Patients who are taking reserpine may experience sudden cardiac arrest or arrhythmia when taking digitalis.

Keep away from light and store in sealed container.

Compound

Tentative 24 months

Shanghai Sine Tianping Pharmaceutical Co., Ltd.

• Founded in:

  1998-05-07

• Address:

  No. 4598, Jindu Road, Minhang District, Shanghai

• Tax NO.:

  91310112832231856K

• Registered Funds:

  154.7 million yuan

• Email:

  Log in to view